Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy. ...
Aug 18, 2016
0
1
(HealthDay)—A wedding band may be powerful medicine against cancer, a new study suggests.
Apr 11, 2016
1
61
Regorafenib (trade name: Stivarga) has been approved since August 2013 for adults with metastatic colorectal cancer in whom previous treatments are no longer effective or for whom these alternatives are not an option. After ...
Jan 13, 2016
0
0
Results of EORTC trial 26101 presented today at The 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology showed that bevacizumab treatment in patients with progressive glioblastoma, despite prolonged ...
Nov 23, 2015
0
3
(HealthDay)—Endovascular (EVAR) repair of abdominal aortic aneurysm is associated with a survival advantage for three years, according to a study published online Sept. 2 in JAMA Surgery.
Sep 4, 2015
0
14
(HealthDay)—For patients undergoing lung transplantation, six-minute walk distance (6MWD) predicts postoperative survival, according to a study published online June 11 in the American Journal of Respiratory and Critical ...
Jun 20, 2015
0
16
A report in the current issue of P&P by a group of Portoguese investigators headed by Antonio Barbosa applies a new psychotherapeutic approach, dignity therapy, to terminally ill patients.
Feb 10, 2015
0
6
Scientists studying brain process involved in sight have found the visual cortex also uses information gleaned from the ears as well as the eyes when viewing the world.
May 25, 2014
2
3
(HealthDay)—Males may be the more vulnerable sex when it comes dying young—not just from accidents, but from a range of causes, a new study finds.
Sep 2, 2013
0
0
Women are 25 percent less likely to die one year after TAVI than men, according to research presented at the ESC Congress today by Dr. Mohammad Sherif from Germany. The findings suggest that TAVI might be the preferred treatment ...
Sep 2, 2013
0
0
